PDF(Pubmed)
Abstract：
OBJECTIVE: The objective of this study was to describe and analyze the clinicopathological features of primary choriocarcinoma (PCC) observed in male patients treated at the Samsung Medical Center between 1996 and 2020.
METHODS: We reviewed the clinical records of 14 male patients with PCC retrospectively to assess their demographic, histological, and clinical characteristics at the time of diagnosis as well as identify the treatment outcomes.
RESULTS: The median age of the patients was 33 years. The primary tumor site was the testicles in seven cases (50%), the mediastinum in six cases (43%), and the brain in one case (7%). The most common metastatic site was the lungs (79%), followed by the brain (43%). All patients with PCC received cytotoxic chemotherapy. Twelve patients had records of their response to cytotoxic chemotherapy; of these 12 patients, eight (8/12, 67%) achieved an objective response, and four (4/12, 33%) achieved stable disease response as the best response during chemotherapy.
CONCLUSIONS: It is known that most male PCC patients eventually develop resistance to cytotoxic chemotherapy and die. Factors such as poor response to chemotherapy, high disease burden, brain metastasis, and hemoptysis at the time of diagnosis are associated with shorter survival time in male PCC patients. Programmed death-1/programmed death-ligand 1 blockade therapy can be a salvage treatment for chemotherapy-resistant male PCC patients.
METHODS: We reviewed the clinical records of 14 male patients with PCC retrospectively to assess their demographic, histological, and clinical characteristics at the time of diagnosis as well as identify the treatment outcomes.
RESULTS: The median age of the patients was 33 years. The primary tumor site was the testicles in seven cases (50%), the mediastinum in six cases (43%), and the brain in one case (7%). The most common metastatic site was the lungs (79%), followed by the brain (43%). All patients with PCC received cytotoxic chemotherapy. Twelve patients had records of their response to cytotoxic chemotherapy; of these 12 patients, eight (8/12, 67%) achieved an objective response, and four (4/12, 33%) achieved stable disease response as the best response during chemotherapy.
CONCLUSIONS: It is known that most male PCC patients eventually develop resistance to cytotoxic chemotherapy and die. Factors such as poor response to chemotherapy, high disease burden, brain metastasis, and hemoptysis at the time of diagnosis are associated with shorter survival time in male PCC patients. Programmed death-1/programmed death-ligand 1 blockade therapy can be a salvage treatment for chemotherapy-resistant male PCC patients.
摘要：
目的：这项研究的目的是描述和分析1996年至2020年在三星医学中心接受治疗的男性患者中观察到的原发性绒毛膜癌（PCC）的临床病理特征。
方法：我们回顾了14例男性PCC患者的临床记录，组织学,诊断时的临床特征以及确定治疗结果。
结果：患者的中位年龄为33岁。7例(50%)原发肿瘤部位为睾丸,纵隔6例（43%），和大脑在一个案例中（7％）。最常见的转移部位是肺（79％），其次是大脑（43%）。所有PCC患者均接受细胞毒性化疗。12名患者有细胞毒性化疗反应的记录；在这12名患者中，八个(8/12，67%)实现了客观反应，4例（4/12，33%）在化疗期间获得了稳定的疾病反应，为最佳反应。
结论：众所周知，大多数男性PCC患者最终对细胞毒性化疗产生耐药性并死亡。对化疗反应不佳等因素，高疾病负担,脑转移瘤,在男性PCC患者中，诊断时咯血与较短的生存时间有关。程序性死亡-1/程序性死亡-配体1阻断疗法可以是对化学疗法耐药的男性PCC患者的挽救性治疗。
方法：我们回顾了14例男性PCC患者的临床记录，组织学,诊断时的临床特征以及确定治疗结果。
结果：患者的中位年龄为33岁。7例(50%)原发肿瘤部位为睾丸,纵隔6例（43%），和大脑在一个案例中（7％）。最常见的转移部位是肺（79％），其次是大脑（43%）。所有PCC患者均接受细胞毒性化疗。12名患者有细胞毒性化疗反应的记录；在这12名患者中，八个(8/12，67%)实现了客观反应，4例（4/12，33%）在化疗期间获得了稳定的疾病反应，为最佳反应。
结论：众所周知，大多数男性PCC患者最终对细胞毒性化疗产生耐药性并死亡。对化疗反应不佳等因素，高疾病负担,脑转移瘤,在男性PCC患者中，诊断时咯血与较短的生存时间有关。程序性死亡-1/程序性死亡-配体1阻断疗法可以是对化学疗法耐药的男性PCC患者的挽救性治疗。
